Marker Therapeutics, Inc.

Monthly Archives: January 2017

Exclusive: Interview With TapImmune, Inc. (NASDAQ: TPIV) President And COO, Dr. John Bonfiglio

If you’re a biotech investor who has not yet heard of TapImmune, Inc. (NASDAQ: TPIV), this clinical-stage immune-oncology company is charging its way through the sector with its cutting-edge vaccine technologies that are attacking ovarian and breast cancer with a whole new vengeance.

Read More

TapImmune Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial

TapImmune, Inc. (NASDAQ: TPIV), today announced that Memorial Sloan Kettering Cancer Center (MSKCC) successfully completed the first safety cohort in its Phase 2 ovarian cancer study.

Read More

TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients

TapImmune, Inc. (NASDAQ: TPIV), today announced the opening of its Phase 2 company-sponsored ovarian cancer study in platinum-sensitive ovarian cancer patients.

Read More

TapImmune To Present At Biotech Showcase 2017

TapImmune, Inc. (NASDAQ: TPIV), today announced its Chairman and CEO, Dr. Glynn Wilson, will present at Biotech Showcase 2017 to be held January 9-11, 2017, at the Hilton San Francisco Union Square.

Read More